Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
EPAS1	rs12712973	A	bevacizumab	efficacy	no	Neovascular age-related macular degeneration. Response was based on the optical coherence tomography (OCT) metric of total retinal thickness (TRT). Change in TRT was calculated between baseline and after 3, 6, 9 or 12 months of treatment, depending on the patient. Eyes with TRT changes >= the 75th percentile were classified as responders; those with changes <= the 25th percentile were classified as nonresponders. Cases = responders; controls = nonresponders. p-value was Bonferroni-corrected for 482 tests (uncorrected p-value = 0.59).	Allele A is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele C.	24070809	1184165267
EPAS1	rs1374749	A	anthracyclines and related substances	efficacy	no	Patients were women with HER2- breast cancer. SNPs in genes in the VEGF pathway were selected to be genotyped (170 plus 16 that were previously investigated for association with response to bevacizumab) and compared between women who received bevacizumab and women who did not. The response was "pathological complete response". This SNP was one of the top 10 SNPs to show association with response to bevacizumab, but did not remain associated after multiple testing correction.	Allele A is not associated with response to anthracyclines and related substances, bevacizumab, cyclophosphamide, docetaxel, epirubicin and taxanes in women with Breast Neoplasms as compared to allele G.	26100253	1447813817
EPAS1	rs3768728	C	anthracyclines and related substances	efficacy	no	Patients were women with HER2- breast cancer. SNPs in genes in the VEGF pathway were selected to be genotyped (170 plus 16 that were previously investigated for association with response to bevacizumab) and compared between women who received bevacizumab and women who did not. The response was "pathological complete response". This SNP was one of the top 10 SNPs to show association with response to bevacizumab, but did not remain associated after multiple testing correction.	Allele C is not associated with response to anthracyclines and related substances, bevacizumab, cyclophosphamide, docetaxel, epirubicin and taxanes in women with Breast Neoplasms as compared to allele T.	26100253	1447813811
EPAS1	rs4953344	C	anthracyclines and related substances	efficacy	no	Patients were women with HER2- breast cancer. SNPs in genes in the VEGF pathway were selected to be genotyped (170 plus 16 that were previously investigated for association with response to bevacizumab) and compared between women who received bevacizumab and women who did not. The response was "pathological complete response". This SNP was one of the top 10 SNPs to show association with response to bevacizumab, but did not remain associated after multiple testing correction.	Allele C is not associated with response to anthracyclines and related substances, bevacizumab, cyclophosphamide, docetaxel, epirubicin and taxanes in women with Breast Neoplasms as compared to allele T.	26100253	1447813803
EPAS1	rs6726454	G	bevacizumab	efficacy	no	Neovascular age-related macular degeneration. Response was based on the optical coherence tomography (OCT) metric of total retinal thickness (TRT). Change in TRT was calculated between baseline and after 3, 6, 9 or 12 months of treatment, depending on the patient. Eyes with TRT changes >= the 75th percentile were classified as responders; those with changes <= the 25th percentile were classified as nonresponders. Cases = responders; controls = nonresponders. p-value was Bonferroni-corrected for 482 tests (uncorrected p-value = 0.004).	Allele G is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele A.	24070809	1184165254
EPAS1	rs7589621	A	bevacizumab	efficacy	no	Neovascular age-related macular degeneration. Response was based on the optical coherence tomography (OCT) metric of total retinal thickness (TRT). Change in TRT was calculated between baseline and after 3, 6, 9 or 12 months of treatment, depending on the patient. Eyes with TRT changes >= the 75th percentile were classified as responders; those with changes <= the 25th percentile were classified as nonresponders. Cases = responders; controls = nonresponders. p-value was Bonferroni-corrected for 482 tests (uncorrected p-value = 0.014).	Allele A is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele G.	24070809	1184165568
EPAS1	rs9679290	C	bevacizumab	efficacy	no	Neovascular age-related macular degeneration. Response was based on the optical coherence tomography (OCT) metric of total retinal thickness (TRT). Change in TRT was calculated between baseline and after 3, 6, 9 or 12 months of treatment, depending on the patient. Eyes with TRT changes >= the 75th percentile were classified as responders; those with changes <= the 25th percentile were classified as nonresponders. Cases = responders; controls = nonresponders. p-value was Bonferroni-corrected for 482 tests (uncorrected p-value = 0.002).	Allele C is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele G.	24070809	1184165250